AcquisitionsJun 8, 2026, 07:11 AM
Incyte to Acquire Vega Therapeutics for $1.25B Upfront
AI Summary
Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion. Star Therapeutics could receive up to an additional $750 million in sales milestone payments. This acquisition will expand Incyte's hematology portfolio by adding VGA039, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease, which has received multiple FDA designations. The transaction is expected to close in the third quarter of 2026, pending regulatory approval, and will result in an R&D charge of approximately $1.25 billion.
Key Highlights
- Incyte to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront.
- Star Therapeutics is eligible for up to $750 million in additional payments based on sales milestones.
- The acquisition adds VGA039, a novel investigational monoclonal antibody, to Incyte's hematology portfolio.
- VGA039 is in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder.
- VGA039 has received Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations from the FDA.
- The transaction is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino review.
- An R&D charge of approximately $1.25 billion is expected in Q3 and full year 2026 GAAP and non-GAAP results.
- Incyte will host an analyst and investor call on June 8, 2026, to discuss the acquisition.
Price Impact
More from INCY